全文获取类型
收费全文 | 4929篇 |
免费 | 213篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 104篇 |
妇产科学 | 99篇 |
基础医学 | 480篇 |
口腔科学 | 101篇 |
临床医学 | 304篇 |
内科学 | 1328篇 |
皮肤病学 | 146篇 |
神经病学 | 239篇 |
特种医学 | 126篇 |
外科学 | 954篇 |
综合类 | 17篇 |
预防医学 | 98篇 |
眼科学 | 122篇 |
药学 | 236篇 |
1篇 | |
中国医学 | 3篇 |
肿瘤学 | 765篇 |
出版年
2024年 | 11篇 |
2023年 | 59篇 |
2022年 | 105篇 |
2021年 | 166篇 |
2020年 | 96篇 |
2019年 | 112篇 |
2018年 | 126篇 |
2017年 | 125篇 |
2016年 | 150篇 |
2015年 | 140篇 |
2014年 | 173篇 |
2013年 | 218篇 |
2012年 | 343篇 |
2011年 | 354篇 |
2010年 | 203篇 |
2009年 | 156篇 |
2008年 | 233篇 |
2007年 | 284篇 |
2006年 | 269篇 |
2005年 | 282篇 |
2004年 | 236篇 |
2003年 | 238篇 |
2002年 | 226篇 |
2001年 | 87篇 |
2000年 | 82篇 |
1999年 | 77篇 |
1998年 | 54篇 |
1997年 | 32篇 |
1996年 | 25篇 |
1995年 | 29篇 |
1994年 | 25篇 |
1993年 | 16篇 |
1992年 | 35篇 |
1991年 | 36篇 |
1990年 | 31篇 |
1989年 | 44篇 |
1988年 | 28篇 |
1987年 | 26篇 |
1986年 | 27篇 |
1985年 | 26篇 |
1984年 | 35篇 |
1983年 | 18篇 |
1982年 | 17篇 |
1981年 | 9篇 |
1979年 | 9篇 |
1978年 | 8篇 |
1977年 | 12篇 |
1974年 | 8篇 |
1973年 | 10篇 |
1971年 | 14篇 |
排序方式: 共有5170条查询结果,搜索用时 15 毫秒
101.
Goto J Otsuka F Kodera R Miyoshi T Kinomura M Otani H Mimura Y Ogura T Yanai H Nasu Y Makino H 《Endocrine journal》2008,55(1):175-181
A 73-year-old Japanese woman was referred for examination of right flank pain and progressive hypertension. Abdominal CT incidentally detected a right adrenal mass 8 cm in size. The tumor exhibited isodensity by CT and contained high-intense lesion by T2-weighted MRI. Scintigraphy with (131) I-metaiodobenzylguanidine and (131) I-adosterol showed no abnormal uptake by whole body scan. Positron emission tomography scan with (18) F-2-fluoro-D-deoxyglucose demonstrated an exclusive uptake in the right adrenal mass. Adrenocortical hormone levels and catecholamine secretion were within normal range; however, the level of serum neuron-specific enolase (NSE) was found to be markedly high. After controlling systemic blood pressure with an alpha1-blocker, the right adrenal tumor was surgically removed, along with the right kidney and inferior vena cava which adhered to it. The tumor was pathologically proven to be leiomyosarcoma, which was immunohistochemically positive with alpha-smooth muscle actin and negative with CD57, S-100 and c-kit proteins. Notably, NSE protein was massively expressed in the resected tumor. After surgery blood pressure was controlled with regular medication and serum NSE levels have since normalized. The possibility of leiomyosarcoma should be kept in mind in adrenal incidentalomas with rapid growth and atypical radiological images. Our findings suggest that circulating NSE levels may be clinically useful for early detection of recurrence. 相似文献
102.
103.
Masato Yoneda Emmanuel Thomas Yoshio Sumida Kento Imajo Yuichiro Eguchi Hideyuki Hyogo Hideki Fujii Masafumi Ono Takumi Kawaguchi Eugene R. Schiff 《Hepatology research》2014,44(14):E499-E502
Serum ferritin was recently reported to have low diagnostic accuracy for the detection of advanced fibrosis in patients with non‐alcoholic fatty liver disease (NAFLD). To corroborate these findings, we investigated the diagnostic accuracy of serum ferritin levels for detecting liver fibrosis in NAFLD patients utilizing a large Japanese cohort database. A total 1201 biopsy‐proven NAFLD patients, seen between 2001 and 2013, were enrolled into the Japan Study Group of NAFLD. Analysis was performed on data from this cohort comparing between serum ferritin levels and hepatic histology. Serum ferritin increased with increasing histological grade of steatosis, lobular inflammation and ballooning. Multivariate analyses revealed that sex differences, steatotic grade and fibrotic stage were independently associated with serum ferritin levels (P < 0.0001, <0.0001, 0.0248, respectively). However, statistical analyses performed using serum ferritin levels demonstrated that the area under the receiver–operator curve for detecting fibrosis was not adequate for rigorous prediction. Several factors including sex differences, steatosis and fibrosis were found to correlate with serum ferritin levels. Therefore, serum ferritin may have low diagnostic accuracy for specifically detecting liver fibrosis in NAFLD patients due to the involvement of multiple hepatocellular processes. 相似文献
104.
105.
Junya Yamamoto Daigo Nakazawa Saori Nishio Yasunobu Ishikawa Minoru Makita Yoshihiro Kusunoki So Nagai Yuichiro Fujieda Masahiko Takahata Kanji Yamada Tsuyoshi Yamamura Akihiko Yotsukura Masanobu Saito Masaru Shimazaki Tatsuya Atsumi 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2020,24(2):146-153
Adynamic bone disease in HD patients is characterized by skeletal resistance to parathyroid hormone (PTH) or suppression of PTH release, leading to a downregulated bone turnover and bone fracture. Hence, we examined the efficacy of weekly teriparatide for HD patients with low PTH indicating adynamic bone disease without a history of parathyroidectomy. Fifteen HD patients with low PTH were recruited in this prospective observational study. Of them, 10 received teriparatide for 12 months and five nontreated patients were enrolled as control. Primary outcomes were defined as the changes in bone mineral density and bone turnover markers. Bone mineral density at the lumbar spine increased by 3.7% and 2.5% at 6 and 12 months, respectively, and bone formation markers increased, while bone resorption markers did not change in the teriparatide group. At 12 months after teriparatide administration, endogenous PTH was secreted followed by the recovery of low bone turnover. 40% of patients in the teriparatide group dropped out due to adverse events and the most common adverse event was transient hypotension. This study suggests that weekly teriparatide for HD patients with low PTH in the absence of parathyroidectomy accelerates bone formation and bone turnover, leading to increased trabecular bone mass and secretion of endogenous PTH. 相似文献
106.
Correlation between lumbar skeletal muscle size and urinary incontinence after radical prostatectomy
107.
Yoshito Tomimaru Nariaki Fukuchi Shigekazu Yokoyama Takuji Mori Masahiro Tanemura Kenji Sakai Yutaka Takeda Masanori Tsujie Terumasa Yamada Atsushi Miyamoto Yasuji Hashimoto Hisanori Hatano Junzo Shimizu Keishi Sugimoto Masaki Kashiwazaki Shogo Kobayashi Yuichiro Doki Hidetoshi Eguchi 《Journal of hepato-biliary-pancreatic sciences》2020,27(8):451-460
108.
109.
110.
Tadao Akizawa Hideki Origasa Chisato Kameoka Yuichiro Kaneko Shigenori Kawasaki Bixalomer Study Group 《Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy》2014,18(2):122-131
Hyperphosphatemia is a prognostic factor for morbidity and mortality in chronic kidney disease. Bixalomer is a nonabsorbable polymer that decreases serum phosphate levels by binding phosphate in the gastrointestinal tract. This study compared the efficacy and safety of bixalomer versus sevelamer hydrochloride for controlling hyperphosphatemia in hemodialysis patients. This was a multicenter, randomized open‐label, non‐inferiority study. The primary endpoint was serum phosphate on completion of treatment. Administration of bixalomer was started at 1.5 g/day and adjusted to a maximum of 7.5 g/day depending on the serum phosphate level. Sevelamer hydrochloride was started at 3.0 or 6.0 g/day and adjusted to a maximum of 9.0 g/day. Treatment was continued for 12 weeks. Fifty‐five patients were randomized to each treatment group. After 12 weeks, the baseline adjusted mean serum phosphate level was 5.87 mg/dL in the bixalomer group and 5.55 mg/dL in the sevelamer group, with a difference of 0.31 mg/dL and 95% confidence interval (CI) of [?0.13 to 0.76]. The upper limit of the 95%CI for the difference of the mean serum phosphate level between the two groups was <1.0 mg/dL, which was the non‐inferiority margin in this study. Thus, non‐inferiority of bixalomer to sevelamer was confirmed. The incidence of adverse events was lower in the bixalomer group, and bixalomer did not promote acidosis. Bixalomer achieved a similar reduction of serum phosphate to sevelamer, while causing fewer adverse reactions. Consequently, the usefulness of bixalomer for treating hyperphosphatemia was confirmed. 相似文献